IART Integra LifeSciences Holdings Corporation

Integra LifeSciences to Reschedule the First Quarter 2024 Financial Results Conference Call to May 6, 2024

Integra LifeSciences to Reschedule the First Quarter 2024 Financial Results Conference Call to May 6, 2024

PRINCETON, N.J., April 18, 2024 (GLOBE NEWSWIRE) --  (NASDAQ: IART), a leading global medical technology company, today announced that it has rescheduled the release of the Company’s first quarter 2024 financial results to Monday, May 6, 2024. In conjunction with the earnings release, Integra’s management team will host a conference call at 8:30 a.m. EDT.

A live webcast will be available on the Investors section of the Company’s website at . For those planning to participate on the call, register  to receive dial-in details and an individual pin. While not required, joining 10 minutes before the event starts is recommended. A webcast replay of the conference call will be available on the  following the call.

About Integra LifeSciences

At Integra LifeSciences, we are driven by our purpose of restoring patients’ lives. We innovate treatment pathways to advance patient outcomes and set new standards of surgical, neurologic, and regenerative care. We offer a comprehensive portfolio of high quality, leadership brands that include Acclarent®, AmnioExcel®, Aurora®, Bactiseal®, BioD™, CerebroFlo®, CereLink® Certas® Plus, Codman®, CUSA®, Cytal®, DuraGen®, DuraSeal®, DuraSorb®, Gentrix®, ICP Express®, Integra®, Licox®, MAYFIELD®, MediHoney®, MicroFrance®, MicroMatrix®, NeuraGen®, NeuraWrap™, PriMatrix®, SurgiMend®, TCC-EZ® and VersaTru®. For the latest news and information about Integra and its products, please visit .

Investor Relations:

Chris Ward

(609) 772-7736

   

Media Contact:

Laurene Isip

(609) 208-8121

 



Integra LifeSciences Holdings Corporation



EN
18/04/2024

Underlying

IARTIntegra LifeSciences Holdings Corporation

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Integra LifeSciences Holdings Corporation

 PRESS RELEASE
Free
IART Integra LifeSci...

Integra LifeSciences to Spotlight CereLink® Intracranial Pressure (ICP...

Integra LifeSciences to Spotlight CereLink® Intracranial Pressure (ICP) Monitoring System at the American Association of Neurological Surgeons (AANS) Annual Scientific Meeting Visit the Codman Specialty Surgical booth to learn how the CereLink ICP Monitoring System provides patients with uncompromised advanced continuous ICP monitoring. PRINCETON, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: IART), a leading global medical technology company, is pleased to announce that following a successful Q1 2024 U.S. relaunch of its , the innovative product will be featured at the upcoming AA...

April 30, 2024 1 EN
 PRESS RELEASE
Free
IART Integra LifeSci...

Integra LifeSciences to Reschedule the First Quarter 2024 Financial Re...

Integra LifeSciences to Reschedule the First Quarter 2024 Financial Results Conference Call to May 6, 2024 PRINCETON, N.J., April 18, 2024 (GLOBE NEWSWIRE) --  (NASDAQ: IART), a leading global medical technology company, today announced that it has rescheduled the release of the Company’s first quarter 2024 financial results to Monday, May 6, 2024. In conjunction with the earnings release, Integra’s management team will host a conference call at 8:30 a.m. EDT. A live webcast will be available on the Investors section of the Company’s website at . For those planning to participate on the ...

April 18, 2024 1 EN
 PRESS RELEASE
Free
IART Integra LifeSci...

Integra LifeSciences Completes the Acquisition of Acclarent, Inc.

Integra LifeSciences Completes the Acquisition of Acclarent, Inc. PRINCETON, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:IART), a leading global medical technology company, today announced it has successfully completed its acquisition of , a pioneer in ear, nose and throat (ENT) surgical interventions. The addition of Acclarent's innovative product portfolio expands the breadth of Integra’s market-leading brands and provides immediate scale and accretive growth via a dedicated sales channel. The acquisition adds $1 billion to the total addressable market of the Company’s offerings, ...

April 1, 2024 1 EN
 PRESS RELEASE
Free
IART Integra LifeSci...

Integra LifeSciences Launches MicroMatrix® Flex to Provide Convenient ...

Integra LifeSciences Launches MicroMatrix® Flex to Provide Convenient Access to Hard-to-Reach Areas in Complex Cases Novel system features flexible tip to deliver flowable version of the Urinary Bladder Matrix (UBM) technology PRINCETON, N.J., March 11, 2024 (GLOBE NEWSWIRE) --  (Nasdaq:IART), today announced MicroMatrix® Flex is now available commercially in the U.S. MicroMatrix Flex is a dual-syringe system enabling the convenient mixing and precise delivery of MicroMatrix® paste to provide convenient access to hard-to-reach spaces and to help prepare an even wound surface in challeng...

March 11, 2024 1 EN
 PRESS RELEASE
Free
IART Integra LifeSci...

Integra LifeSciences Announces Leadership Transition Plan

Integra LifeSciences Announces Leadership Transition Plan Jan De Witte to retire as CEO by the end of 2024Stuart Essig appointed executive chairman of the Board PRINCETON, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- (“Integra” or “the Company”) (NASDAQ: IART), a leading global medical technology company, today announced that Jan De Witte has informed the Board of Directors (the “Board”) of his intention to retire from his position as president and chief executive officer of Integra following the appointment of a successor, which the Company expects to occur by the end of 2024. The Compa...

February 28, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch